Development of new plasmid DNA vaccine vectors with R1-based replicons
© Bower and Prather; licensee BioMed Central Ltd. 2012
Received: 10 July 2012
Accepted: 3 August 2012
Published: 13 August 2012
Skip to main content
© Bower and Prather; licensee BioMed Central Ltd. 2012
Received: 10 July 2012
Accepted: 3 August 2012
Published: 13 August 2012
There has been renewed interest in biopharmaceuticals based on plasmid DNA (pDNA) in recent years due to the approval of several veterinary DNA vaccines, on-going clinical trials of human pDNA-based therapies, and significant advances in adjuvants and delivery vehicles that have helped overcome earlier efficacy deficits. With this interest comes the need for high-yield, cost-effective manufacturing processes. To this end, vector engineering is one promising strategy to improve plasmid production.
In this work, we have constructed a new DNA vaccine vector, pDMB02-GFP, containing the runaway R1 origin of replication. The runaway replication phenotype should result in plasmid copy number amplification after a temperature shift from 30°C to 42°C. However, using Escherichia coli DH5α as a host, we observed that the highest yields of pDMB02-GFP were achieved during constant-temperature culture at 30°C, with a maximum yield of approximately 19 mg pDNA/g DCW being observed. By measuring mRNA and protein levels of the R1 replication initiator protein, RepA, we determined that RepA may be limiting pDMB02-GFP yield at 42°C. A mutant plasmid, pDMB-ATG, was constructed by changing the repA start codon from the sub-optimal GTG to ATG. In cultures of DH5α[pDMB-ATG], temperature-induced plasmid amplification was more dramatic than that observed with pDMB02-GFP, and RepA protein was detectable for several hours longer than in cultures of pDMB02-GFP at 42°C.
Overall, we have demonstrated that R1-based plasmids can produce high yields of high-quality pDNA without the need for a temperature shift, and have laid the groundwork for further investigation of this class of vectors in the context of plasmid DNA production.
Gene therapies and DNA vaccines have gained attention in recent years as potential treatments for a range of acquired and infectious diseases. In particular, therapies that use plasmid DNA (pDNA) as a vector are attractive because they have a good safety profile and are relatively easy to manufacture using Escherichia coli as a host. Interest in the field has also been stimulated by the approval of several veterinary gene-based therapeutics and on-going clinical trials of plasmid-based human therapeutics . In addition, a recent Phase 2 trial of an adenoviral-vectored DNA vaccine yielded disappointing results , fueling safety and efficacy concerns surrounding adenoviral vaccines. Finally, recent advances in delivery vehicles and adjuvants for use in concert with naked plasmid DNA have helped increase the efficacy of these therapies . Gene delivery via electroporation has especially reinvigorated the field; early studies suggest that DNA delivered using electroporation devices may elicit immune responses on par with more traditional vaccines .
Currently, plasmid DNA is produced almost exclusively using vectors containing the high-copy pUC replicon. pUC-based plasmids are derivatives of the ColE1 origin of replication that lack the RNA one modulator (Rom) protein and contain a point mutation in the RNA II sequence. These two mutations together give increasingly higher copy numbers as the culture temperature is increased from 30°C to 42°C . Extensive process development has resulted in the design of very high-yield, fed-batch processes for the production of pUC vectors . However, with the exception of the pCOR family of plasmids based on the R6K replicon [7, 8], no other plasmid replicons have been investigated for pDNA production.
One promising alternative to currently-available plasmids are vectors based on the so-called runaway R1 origin of replication. There are numerous reports in the early plasmid literature about these high-copy mutants of the E. coli plasmid R1. Runaway replication plasmids lose control of their copy number at high temperatures (> 37°C), resulting in plasmid copy numbers as high as 2000 copies per chromosome . These high copy numbers suggest that runaway replication plasmids would be well-suited for plasmid DNA production. The mechanism of R1 replication has been described extensively elsewhere . In short, two point mutations confer the runaway replication phenotype: one that decreases transcription of the antisense RNA repressor copA, and a second that increases transcription of the replication initiator protein gene, repA, in a temperature-dependent fashion . Runaway R1-based plasmids have been used successfully for temperature-induced recombinant protein production [12–15], but they have yet to be investigated in the context of plasmid DNA production for therapeutic applications.
This work describes the construction and characterization of a new DNA vaccine vector, pDMB02-GFP, containing the runaway R1 origin of replication that is capable of producing high plasmid DNA yields. The yield trends of our new vector were compared to the yields of both the replicon source plasmid and a pUC-based DNA vaccine vector at the shake flask scale in rich medium. We also monitored the mRNA and protein expression of the plasmid replication initiator, repA, to gain insight into the observed trends.
There are several possible explanations for the experiment-to-experiment variability observed in the maximum yield of pDMB02-GFP. The use of a rich medium (LB) may be partially responsible, as the exact medium composition can vary from run-to-run. However, the mechanism of R1 replication is not designed for tight control of plasmid copy number. Instead, the goal is to prevent the copy number from dropping below one per cell – a concern that is more relevant for the low-copy, wild-type R1 plasmid . This may result in increased clone-to-clone variability when the plasmid copy number is significantly higher than one, as observed in the runaway mutants.
We were surprised to observe that pCP40 and pDMB02-GFP did not show the dramatic temperature-induced amplification reported in the early literature characterizing the runaway R1 replicon [9, 16]. In particular, we expected greater copy number control before the temperature shift; however, we are not the first group to observe that runaway replication is not completely suppressed at 30°C [14, 19]. To further investigate the temperature-dependent behavior of pDMB02-GFP we pursued additional studies at the RNA and protein levels.
Specific yield, plasmid copy number, and repA expression in cultures of DH5α[pDMB02-GFP] with and without a temperature shift
Specific Yield (mg pDNA/g DCW)
42 ± 2
1.07 ± 0.10
1.07 ± 0.16
1.5 ± 0.1
90 ± 9
0.69 ± 0.02
0.32 ± 0.05
4.4 ± 0.2
144 ± 3
0.77 ± 0.25
0.22 ± 0.08
7.0 ± 0.3
212 ± 72
1.40 ± 1.74
0.27 ± 0.36
2.2 ± 0.0
153 ± 3
12.50 ± 2.55
3.40 ± 0.78
4.2 ± 0.1
105 ± 39
28.15 ± 1.48
11.21 ± 4.33
5.1 ± 0.6
177 ± 29
24.60 ± 0.14
5.78 ± 1.12
The repA mRNA expression data pointed to the possibility of a post-transcriptional limitation on plasmid yield at 42°C. One option for relieving this limitation is to increase expression of RepA. To this end, we changed the RepA start codon in pDMB02-GFP from GTG to ATG, resulting in the plasmid pDMB-ATG. There is evidence in the literature that genes with a GTG start codon are typically translated several-fold less efficiently than genes with an ATG start codon . We chose a start codon mutation instead of a promoter replacement to minimize disruption of the other elements of the replicon. Also, since RepA is primarily cis acting , supplying RepA exogenously from either the chromosome or an additional plasmid was not a viable strategy for increasing RepA availability.
Specific yield, plasmid copy number, and repA expression from cultures of DH5α[pDMB-ATG] with and without a temperature shift
Specific yield (mg pDNA/g DCW)
13 ± 3
0.09 ± 0.01
0.30 ± 0.09
0.2 ± 0.1
20 ± 4
0.06 ± 0.00
0.13 ± 0.03
1.0 ± 0.0
54 ± 1
0.20 ± 0.02
0.15 ± 0.02
2.3 ± 0.3
96 ± 27
0.32 ± 0.02
0.14 ± 0.04
1.9 ± 0.1
243 ± 32
1.00 ± 0.08
0.17 ± 0.03
5.1 ± 1.9
407 ± 210
15.20 ± 1.13
1.56 ± 0.83
11.4 ± 1.7
476 ± 176
9.85 ± 0.64
0.86 ± 0.34
Taken with the RNA expression data, the protein expression data for pDMB02-GFP suggest RepA protein levels may be limiting replication at 42°C. While we cannot deconvolute whether more RepA expression is leading to higher copy number or vice versa, it is clear that RepA protein is depleted after 8 hours at 42°C for the wild-type plasmid, and that the start codon mutation increases RepA protein levels at this time point. Despite this limitation, we have shown that high yields of pDMB02-GFP can be produced during constant-temperature growth at 30°C without a temperature shift. This is particularly advantageous for production-scale runs, as it reduces the complexity of the process and allows the culture to achieve a higher final cell density and higher volumetric yields. In addition, the mutant plasmid pDMB-ATG seems to perform better at 42°C, making it the more attractive vector if a temperature-shift process is desired.
These data show that neither the elevated temperature nor the start codon mutation had a negative impact on plasmid quality. Thus, pDMB02-GFP and pDMB-ATG are capable of producing not only high yields of plasmid DNA, but high quality product as well.
In this work, we have described construction of a new DNA vaccine vector, pDMB02-GFP, containing the runaway R1 origin of replication. Our new vector produced high yields of high-quality plasmid DNA during constant-temperature culture at 30°C. The runaway R1 replicon has been reported to result in a temperature-dependent loss of copy number control, with higher copy numbers at higher temperatures. However, while we observed some temperature-induced amplification of pDMB02-GFP shortly after a temperature shift, at longer times, the yield at 30°C was often higher than that at 42°C. Using RNA and protein expression measurements, we demonstrated that RepA protein availability may be limiting pDMB02-GFP yield at 42°C. To increase RepA protein levels, we constructed a second vector, pDMB-ATG, in which the start codon of repA was changed from the sub-optimal GTG to ATG. RepA was detected in cultures of DH5α[pDMB-ATG] up to 8 hours after a temperature shift and was accompanied by enhanced temperature-dependent plasmid amplification.
Overall, we have developed a new set of high-yielding DNA vaccine vectors that are well suited to processes run at low temperatures (pDMB02-GFP) as well as processes that include a temperature shift (pDMB-ATG). Future work to systematically vary the expression of RepA and to determine the resulting effects on specific yield will guide additional efforts to maximize plasmid production. Furthermore, the mechanistic insight into the factors limiting R1 replication gained in this work can serve as the basis of scale-up studies to investigate R1-based DNA vaccine vectors under industrially-relevant conditions.
E. coli strain DH5α [F- φ80lacZΔM15 Δ( lacZYA argF)U169 deoR recA1 endA1 hsdR17(rk -, mk +) phoA supE44 thi-1 gyrA96 relA1 λ- and the plasmid pVAX1 (2999 bp) were purchased from Invitrogen (Carlsbad, CA). pVAX1-GFP (3642 bp) was constructed by cloning the superfolding green fluorescent protein (sGFP) gene  into the multi-cloning site of pVAX1. The sGFP gene was obtained from pTrcsGFP, a gift from the Gregory Stephanopoulos laboratory (Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA). pCP40 (5029 bp) was constructed by Remaut et al.  and was obtained from the Belgian Coordinated Collections of Microorganisms BCCM/LMBP plasmid collection (accession number LMBP 951).
To construct pDMB02-GFP, a 1938-bp fragment of pVAX1 containing the human cytomegalovirus (CMV) immediate-early promoter/enhancer, bovine growth hormone (BGH) polyadenylation signal, and kanamycin resistance gene was PCR-amplified using primers containing AvrII and SbfI restriction sites. A 3073-bp fragment of pCP40 containing the R1 origin of replication along with the repA copA, and copB gene sequences was also PCR-amplified with the same restriction sites. The pVAX1 and pCP40 fragments were ligated to construct the plasmid pDMB02. The sGFP gene was cloned into the NheI and XhoI restriction sites downstream of the CMV promoter/enhancer. A Kozak sequence was also inserted at the start of the sGFP gene by adding the sequence ACC before the start codon and a valine codon (GTG) following the start codon. The Kozak sequence should help facilitate sGFP gene expression in mammalian cells . The resulting vector, pDMB02-GFP, was 5668 bp in size (Figure 1). Correct construction was confirmed by restriction digests and sequencing.
After PCR, the template plasmid was digested using DpnI, and after clean-up the reaction was used to transform ElectroMAX DH10B cells (Invitrogen). Positive transformants were selected on LB/agar plates containing 50 μg/mL kanamycin, and the presence of the start codon mutation was verified by sequencing.
Frozen working seed banks of DH5α[pDMB02-GFP] and DH5α[pDMB-ATG] were prepared by transforming subcloning-efficiency, chemically-competent DH5α (Invitrogen) with purified plasmid. Positive transformants were selected on LB/agar plates containing 25 μg/mL kanamycin. After overnight incubation at 30°C, a single colony was used to inoculate 3 mL of LB medium containing 25 μg/mL kanamycin. The culture was incubated overnight at 30°C. The next day, 500 μL of overnight culture was used to inoculate 50 mL of LB medium containing 25 μg/mL kanamycin in a 250-mL shake flask. The culture was incubated at 30°C until mid-exponential phase (OD600 approximately equal to 0.5), at which time 900 μL of culture was added to 900 μL of cold 30% (v/v) glycerol in a cryogenic vial and immediately stored at −80°C. Working seed bank vials were discarded after two freeze-thaw cycles.
Difco LB Broth, Miller (BD; Franklin Lakes, NJ) was used for shake flask cultures and contained 10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl. Cell density was monitored using OD600 measurements on a DU800 spectrophotometer (Beckman Coulter; Indianapolis, IN). All cultures were mixed and aerated by agitation at 250 rpm unless otherwise specified.
Temperature-induced plasmid amplification was studied using temperature shift experiments as follows: 100 to 110 mL of LB medium containing 25 μg/mL kanamycin (or 100 µg/mL ampicillin for pCP40) was inoculated to an initial OD600 = 0.00025 using working seed bank. The very low initial OD600 was chosen to avoid glycerol carry-over from the working seed bank vial. The cultures were incubated in 500-mL baffled shake flasks at 30°C until the desired growth phase was achieved (typically OD600 = 0.5 – 1.0) at which point half of the culture volume was transferred to a 250-mL shake flask and incubated at 42°C. The remaining culture was transferred to a 250-mL shake flask and incubated at 30°C.
5 mL LB containing 25 μg/mL kanamycin was inoculated with 20 μL of DH5α[pDMB02-GFP] working seed bank and incubated at 30°C. Aliquots of the culture were collected in late exponential (OD600 = 1.1), early stationary (OD600 = 2.3), and late stationary (OD600 = 2.8) growth phases and used to inoculate 50 mL LB containing 25 μg/mL kanamycin to an initial OD600 = 0.01. The resulting cultures were incubated at 30°C for at least 24 hours. Samples were taken periodically to measure cell growth and plasmid production.
Plasmid copy number was determined from 100 μL of culture using the quantitative PCR (qPCR) method described by Bower et al.  In short, SYBR Green was used to detect amplification of plasmid-based and chromosomal gene targets from total DNA samples diluted 5-fold (if necessary) to be within the linear range of the assay. The ΔΔCT method  was used to calculate plasmid copy number.
Plasmid DNA was quantified from crude lysates prepared from OD600 = 10 cell pellets using the method described previously . Briefly, crude lysates were run on a Gen-Pak FAX anion-exchange column (Waters Corporation; Milford, MA) and pDNA was eluted using a NaCl gradient. Plasmid detected by absorbance at 260 nm was quantified using a standard curve of known quantities of purified plasmid DNA. Specific yield could then be calculated using the correlation that 1 OD600 unit = 0.4 g DCW/L culture.
repA mRNA expression was measured using a quantitative real-time PCR assay. RNA was purified from OD600 = 1 pellets using the Illustra RNAspin Mini RNA Isolation Kit (GE Healthcare; Piscataway, NJ). 1 g/L lysozyme was used for cell lysis in the first step of the protocol. Due to the high plasmid DNA content of the strains used in this work, an additional DNase digestion was required after the RNA purification step to remove contaminating DNA. 43 μL purified RNA was digested with 2 μL DNase I (New England Biolabs) in 5 μL of the supplied reaction buffer for 10 min. at 37°C. RNA was purified from the other reaction components using the RNA Cleanup protocol from the RNeasy Mini Kit (Qiagen; Valencia, CA). The RNA content of each sample was measured using a NanoPhotometer (Implen; Westlake Village, CA), and 800 ng of RNA was converted to cDNA using the QuantiTect Reverse Transcription Kit (Qiagen). Control reactions containing water instead of the reverse transcriptase enzyme were included for each sample.
Quantitative PCR was performed on a 7300 Real-Time PCR System (Applied Biosystems; Carlsbad, CA). The desired reference sample was diluted 2- to 1000-fold to prepare a standard curve. repA mRNA was detected using gene-specific primers (forward primer: 5’-CAGAGCTTAAGTCCCGTGGAAT-3’, reverse primer: 5’-TGACGTTCTCTGTTCGCATCA-3’) designed by Primer Express 3.0 software (Applied Biosystems). Each 25-μL reaction contained 1X Brilliant II SYBR Green QPCR High ROX Master Mix (Agilent Technologies; Santa Clara, CA), 200 nM each of the forward and reverse primers, and the experimental sample diluted 100-fold. The thermal cycling conditions were a 95°C hold for 10 min., followed by 40 cycles of 95°C for 30 sec. and 60°C for 1 min. Dissociation-curve analysis was also performed to check for the presence of primer dimers or non-specific products. Results were analyzed using the Applied Biosystems Sequence Detection Software (v. 1.3.1).
Polyclonal RepA antiserum was a generous gift from Prof. Rafael Giraldo (Centro de Investigaciones Biológicas, Madrid, Spain) and was prepared as described by Giraldo-Suárez et al. . To reduce background binding, the RepA antiserum was incubated with plasmid-free DH5α lysate to precipitate non-specific E. coli-reactive antibodies. A lysate of plasmid-free DH5α was prepared from 50 mL of mid-exponential phase culture grown in LB medium by freeze-thaw and sonication in buffer containing 10 mM Tris–HCl at pH 7.5, 140 mM NaCl, 1% Triton X-100, 1% BSA, 1% sodium deoxycholate, and 1 Complete Mini Protease Inhibitor Cocktail tablet (Roche; Indianapolis, IN) per 10 mL. The DH5α lysate was added to an aliquot of RepA antiserum in a 1:1 ratio and incubated at room temperature for 5.5 hr with gentle rocking. After incubation, the antiserum was centrifuged for 20 min. at 20000 x g and 4°C. The supernatant was recovered and stored in single-use aliquots at −80°C.
Cell lysates were prepared by resuspending pellets prepared from 4–5 mL of culture in 1 mL 10 mM Tris–HCl at pH 8.0. The 1-mL suspension was added to approximately 500 μL of 0.1 mm glass beads (Scientific Industries; Bohemia, NY) in a 1.7-mL microcentrifuge tube. The suspension and glass beads were vortexed at maximum speed for 5 min. followed by centrifugation for 20 min. at 14000 x g and 4°C. The supernatant was recovered and stored at −30°C.
Total protein content of the lysates was measured using the modified Bradford assay described by Zor and Selinger . A 7.5-μl aliquot of each lysate containing 2 μg total protein (balance water) was prepared. An equal volume of Laemmli buffer containing 5% (v/v) β-mercaptoethanol was added to each aliquot, and the samples were incubated at 100°C for 5 min. Samples were loaded on a 10% Mini-PROTEAN TGX Gel with 15 x 15-μL wells (Bio-Rad; Hercules, CA) and run at 200 V for 30 min in tris/glycine/SDS buffer.
Protein separated by SDS-PAGE was transferred to a nitrocellulose membrane (Pall Corporation; Pensacola, FL) for 1 hr at 100 V using a Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad) with transfer buffer containing 25 mM Tris, 192 mM glycine, and 20% (v/v) methanol at pH 8.3. After transfer, the membrane was blocked with a 5% (w/v) bovine serum albumin solution prepared in TBS (2.42 g/L Tris, 29.24 g/L NaCl, pH 7.5) at room temperature for 2 hr. After two 10-min. washes with TBST solution (TBS + 0.05% v/v Tween-20), the membrane was incubated with a 1:1000 dilution of RepA antiserum in TBS containing 10% glycerol for 2 hr at room temperature. The membrane was washed three times with TBST for 10 min. each, and was then incubated with a 1:5000 dilution of goat anti-rabbit IgG-HRP secondary antibody (Santa Cruz Biotechnology; Santa Cruz, CA) in TBS for 1 hr. After two 10-minute washes with TBST and one 10-minute wash with TBS, secondary antibody binding was visualized using Western Blotting Luminol Reagent (Santa Cruz Biotechnology) following the manufacturer’s instructions.
To verify that the band being detected on the Western blots was indeed RepA, a positive control vector was constructed by cloning the repA gene into the BamHI/HindIII sites of pETDuet-1 (EMD Millipore; Billerica, MA), in-frame with an N-terminal 6X His tag. The resulting plasmid, pETDuet-repA, was used to express RepA-His in E. coli BL21 Star (DE3) (Invitrogen). 50-mL LB cultures of BL21 Star (DE3) containing either pETDuet-repA or pETDuet-1 and 100 μg/mL ampicillin were grown at 30°C with 250 rpm shaking and induced with 0.5 mM IPTG at an OD600 of approximately 0.5. Six hours after induction, 20-mL aliquots of culture were harvested by centrifugation. Lysates were prepared from the pellets using disruption with 0.1 mm glass beads (Scientific Industries) in buffer containing 7 M urea, 0.1 M NaH2PO4, and 0.01 M Tris–HCl at pH 8.0.
Plasmid DNA purified from OD600 = 2 pellets using the Zyppy Plasmid Miniprep Kit (Zymo Research Corporation; Irvine, CA) was run on a 0.7% agarose gel at 90 V for 60 min. to separate the supercoiled, nicked (open-circle), and linear isoforms. The separated DNA was visualized by staining the gel with 0.5 μg/mL ethidium bromide.
The authors would like to acknowledge Prof. Rafael Giraldo (Centro de Investigaciones Biológicas, Madrid, Spain) for generously providing the RepA antiserum, and Ms. Shan Tie (MIT Undergraduate Research Opportunities Program (UROP)) for her assistance with qRT-PCR assay development. Funding for this work was provided by Pfizer Inc. and the MIT-Portugal Program.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.